Klomipramin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klomipramin

Quick Facts

Property Description
Active ingredient Clomipramine Hydrochloride
Form Tablet, Capsule, Solution for injection
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Modulation of mood and behavior
Origin Synthetic compound

Defining Klomipramin: Identity, Type, and Origin

Klomipramin is a prescription-only medicine chemically classified as a Tricyclic Antidepressant (TCA), forming a distinct class of psychoactive drug used to manage central nervous system function. The active pharmaceutical ingredient is Clomipramine, commonly prepared as the stable Hydrochloride salt. This medication is a synthetic compound whose foundational structure is a Dibenzazepine derivative. Klomipramin is clinically recognized for its enduring utility, even as newer classes of antidepressant agents have been developed.


Composition and Available Pharmaceutical Forms

The core composition of Klomipramin centers on the single active ingredient, Clomipramine Hydrochloride. This agent is manufactured in several standard dosage form(s) to support different routes of administration. Patients are typically prescribed Klomipramin as a solid tablet or capsule for oral intake. The medicine is also available as a sterile solution for injection to allow for parenteral administration in clinical settings. Unlike many generic TCAs, Klomipramin is often specifically chosen when a high degree of serotonin reuptake inhibition is desired.


Klomipramin's General Purpose as an Antidepressant Agent

The general purpose of Klomipramin is to act as an established antidepressant agent by influencing critical chemical messengers in the brain. Its function is primarily attributed to its potent effect as a Serotonin-Norepinephrine Reuptake Inhibitor, which means it is designed to modulate the levels of serotonin and norepinephrine to help re-establish stability in neural pathways. The drug’s therapeutic role is to provide a regulatory effect on the central nervous system, addressing imbalances related to mood and behavior.

Regulatory References

  1. Clomipramine - StatPearls - NCBI Bookshelf
  2. Clomipramine: MedlinePlus Drug Information

What side effects are possible with Klomipramin?

Possible Side Effects and Safety Information

The safety profile of Klomipramin (Clomipramine) is documented by health regulators, classifying adverse reactions by frequency and affected body system. These statements reflect information from clinical studies and post-marketing surveillance, providing a factual outline of potential risks.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by their approximate rate of occurrence, ranging from Very Common (ge 1 in 10 patients) to Not Known (cannot be estimated from available data).

Frequency Category Examples of Affected Systems/Effects
Very Common Nervous System (drowsiness, dizziness, tremor); Gastrointestinal (dry mouth, constipation); General (fatigue, increased sweating)
Common Cardiac (tachycardia); Eye Disorders (blurred vision); Psychiatric (restlessness, appetite increase)
Uncommon Nervous System (seizures); Psychiatric (psychosis activation)

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions are rare but clinically significant events that have been officially documented. These include cardiac effects (e.g., arrhythmias, conduction defects like QT interval prolongation), Neuroleptic Malignant Syndrome (NMS), agranulocytosis (a severe blood disorder), hepatitis, and instances of suicidal ideation/behavior, particularly during the initial phase of treatment or dose adjustment.

Safety Restrictions define when the medicine should not be used (contraindications). Klomipramin is generally contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), in the recovery phase after myocardial infarction, and in patients with certain congenital heart conditions.

Population-Specific Notes

Regulators provide specific cautions for certain groups. Older adults may have an increased risk of adverse effects such as sedation and orthostatic hypotension. Use during pregnancy and lactation requires caution, as the substance is known to cross the placenta and is excreted in breast milk.

Overdose and Emergency Response

Overdose and when to seek help

The Klomipramin overdose profile, as documented in regulatory labeling, involves serious central nervous system and cardiovascular events. Overdose is officially classified as potentially fatal, mandating immediate and urgent medical attention.

Documented Overdose Manifestations

System Manifestations Listed in Official Labeling
Central Nervous System (CNS) Stupor, coma, agitation, confusion, muscular rigidity, and convulsions (seizures).
Cardiovascular System Low blood pressure (hypotension), fast heart rate (tachycardia), conduction disturbances, and life-threatening arrhythmias including torsades de pointes.
Severe Outcomes Cardiac arrest, respiratory failure, and Serotonin Syndrome (a potentially life-threatening reaction).

Required Emergency Actions

Due to the severity, emergency medical attention must be sought immediately for all suspected overdoses. Official guidance requires hospitalization and close surveillance for at least 72 hours to monitor for potential relapses, especially regarding cardiac function. Accidental ingestion of any amount by a child is officially regarded as serious and potentially fatal. Treatment is defined as symptomatic and supportive, including interventions such as gastric lavage and the administration of activated charcoal. The regulatory labels state that no specific antidote is known for Klomipramin overdose.

Therapeutic Uses of Klomipramin

What Klomipramin Treats: Main Uses and Benefits

Klomipramin is applied across domains where additional symptomatic support is needed, primarily focusing on conditions characterized by periods of heightened symptoms that interfere with daily functioning. It plays a role in managing specific psychiatric disorders and their related distressing manifestations.

It is commonly used to help with Obsessive-Compulsive Disorder (OCD), Major Depressive Disorder (MDD), and episodic conditions like Panic Disorder, and may also be applied when appropriate to ease certain physical symptoms such as chronic nerve-related pain and the pathological loss of muscle tone (cataplexy).

“The treatment may provide supportive therapeutic benefit that assists with functional stability during periods when symptoms are more noticeable.”


Quick Fact: Relief for Obsessional Burden

Symptom Focus Context of Use Patient Benefit
Intrusive thoughts and rituals symptoms that create noticeable functional strain may help patients cope more steadily with symptom fluctuations
Severe depression and low mood is relevant when symptoms create noticeable functional strain contributes to improved comfort during periods of heightened symptoms
Episodic panic and neuropathic discomfort Applied across domains where additional symptomatic support is needed may assist with maintaining a sense of stability when symptoms are more noticeable

Eligibility and Restrictions for Use

Official Eligibility Rules for Clomipramine Use

Regulatory authorities define strict population guidelines detailing who can and cannot use Klomipramine. The official label establishes absolute contraindications that prohibit use in certain groups. This includes individuals with known hypersensitivity to clomipramine or other tricyclic antidepressants (TCAs), and patients who are in the acute recovery period immediately following a myocardial infarction.

Clomipramine is also strictly contraindicated for patients with severe hepatic impairment, untreated narrow-angle glaucoma, or urinary retention. Furthermore, it must not be used concurrently with, or within 14 days of, a monoamine oxidase inhibitor (MAOI).

Age and Conditional Restrictions

Population Group Eligibility Status (Regulatory)
Children under 10 Not recommended; use not established
Adolescents (10+) Allowed for Obsessive-Compulsive Disorder (OCD) only
Older Adults (Geriatric) Requires reduced starting dosage and careful monitoring
Pregnancy/Lactation Not recommended; use only if benefit justifies risk
Renal/Cardiovascular Impairment Requires caution and close monitoring

These rules ensure that the medicine is reserved for eligible adult and pediatric patients (aged 10 years and older for OCD) who do not possess any of the listed contraindications or severe restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Klomipramin's interaction profile is primarily governed by its metabolism via liver enzymes and its specific action on neurotransmitter systems, as documented in regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Interaction Categories

Interaction Type Interacting Agent Category (Official Outcome)
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue. (Prohibited due to the risk of Serotonin Syndrome.)
Exposure Modification CYP2D6 and CYP1A2 Inhibitors (e.g., Fluvoxamine, Fluoxetine). (Increases Klomipramin plasma concentrations.)
Pharmacodynamic Synergy Other Serotonergic Drugs (e.g., Triptans, St. John's Wort). (Elevates the risk of Serotonin Syndrome.)
Cardiac Risk Drugs that Prolong the QTc Interval. (Formal restriction due to arrhythmia risk.)

Co-administration with MAOIs requires mandatory separation periods: a 14-day wash-out period is required when starting Klomipramin after discontinuing most MAOIs, and vice-versa. A shorter 48-hour separation is required for Moclobemide. Alcohol consumption is documented to worsen the central nervous system effects of Klomipramin, such as sedation. Specific interacting agents that increase plasma concentrations include Haloperidol and Methylphenidate. Furthermore, an increased risk of interaction-related toxicity exists for individuals classified as CYP2D6 Poor Metabolizers when co-administered with CYP2D6 inhibitors.

Mechanism of Action

Klomipramin, a tricyclic compound, functions primarily as a dual inhibitor of the reuptake of both serotonin (5-HT) and norepinephrine (NE). This action occurs at the presynaptic terminals where Klomipramin competitively blocks the reuptake pumps, the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). Inhibition of these transporters leads to an elevated concentration of 5-HT and NE within the synaptic cleft.

The drug's active metabolite, desmethylclomipramine, contributes to the overall pharmacologic profile, demonstrating preferential inhibitory activity toward the NET. In addition to its monoamine reuptake blockade, Klomipramin is an antagonist at several other receptor sites. These include muscarinic cholinergic receptors, histamine H1 receptors, and alpha1-adrenergic receptors. This interaction at multiple targets results in a broad modulation of central nervous system signaling pathways.

Dosage and Administration Information

Klomipramin (Clomipramine) is an oral medication available in forms such as capsules and tablets, with usage structured by guidelines on administration and dosing protocols. Administration begins with a low initial daily dose, typically 25 mg for adult Obsessive-Compulsive Disorder (OCD) or 10 mg for older adult patients, to establish patient tolerance. The total daily dose is subsequently increased gradually—a process known as titration—over approximately two weeks until the target effective dose is achieved.

Dosing is governed by established guidelines and is condition-specific; for instance, the maximum dose for adult OCD is limited to 250 mg per day, whereas the upper limit for treating cataplexy is typically 75 mg per day. Initial doses are often divided and taken with meals to reduce the chance of gastrointestinal discomfort.

Once established, the daily maintenance dose may be consolidated and taken as a single administration at bedtime to help mitigate potential daytime sleepiness. Age-group-specific instructions mandate a lower starting dose and cautious titration for older adults. Pediatric dosing for OCD (ages 10 and above) must not exceed 200 mg or 3 mg/ kg per day, whichever is smaller. Furthermore, treatment must never be stopped abruptly; established procedure requires that the dose be gradually tapered prior to full discontinuation. Instructions also specify that prolonged-release or film-coated tablets must not be broken or halved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Klomipramin

Evidence for use in Obsessive-Compulsive Disorder (OCD)

The research exploring the profile of this medicine for Obsessive-Compulsive Disorder (OCD) primarily involves short-term Randomized Controlled Trials (RCTs). Researchers monitored outcomes describing episodic or acute changes by using standardized tools, most notably the Yale-Brown Obsessive Compulsive Scale (YBOCS), to quantify the intensity and patterns of compulsive and obsessive behaviors. Studies evaluated the medicine in adults diagnosed with moderate-to-severe OCD, and some separate trials were applied in studies examining patient-reported experiences in children and adolescents.

Findings describe patterns observed in the studies, with data showing patterns related to measured differences from those seen in the control groups during the short-term duration of the trials. What remains uncertain relates to the evidence extending beyond these initial evaluations. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding the sustained stability or maintenance of these measured changes.


Evidence for use in Major Depressive Disorder (MDD)

The research base for Major Depressive Disorder (MDD) consists of historical clinical trials and comparison studies against other classes of antidepressant drugs. Research examined outcomes related to systemic or functional imbalance, specifically monitoring the reduction in depressive symptom severity using standard rating scales. Pooled analyses of the overall drug class described the frequency of monitoring risk-related outcomes in cohorts of young adults, adolescents, and children. Some historical expert summaries indicate that the evidence comparing this medicine's measured outcomes to modern agents is limited. A key limitation is that evidence quality varies across studies due to the reliance on older, historically established trials.


Evidence for use in Episodic Conditions (Panic Disorder)

This medicine was studied for its profile in treating Panic Disorder, a condition characterized by fluctuating or episodic manifestations. Clinical trial measurements monitored the frequency and intensity of panic attacks. Follow-up studies, which monitored responses over defined time intervals, described patterns related to measured outcomes for periods extending up to a year. Evidence is limited in that some supporting evidence relies on historical or open-label studies.


What is Still Uncertain About Klomipramin Research

Comparative evidence against many newer treatment options is limited, particularly in the form of modern, large-scale clinical trials. There is limited information for long-term outcomes regarding both effectiveness and tolerability, especially for maintenance treatment across all conditions. Furthermore, data for certain groups remain insufficient, with limited information on the medicine's profile in special populations such as older adults and individuals with complex co-existing conditions.

Key Studies & References Clomipramine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Klomipramin (FAQ)


Q: What is the main difference between Klomipramin and other common antidepressants?

Official documents classify Klomipramin as a Tricyclic Antidepressant (TCA). Its primary mechanism is described as the potent inhibition of the reuptake of two key brain chemicals: serotonin and norepinephrine. Many newer antidepressants primarily target only serotonin or have a different main mechanism.


Q: How long does it usually take to feel the effects of Klomipramin?

Clinical information indicates that the drug’s active levels, or steady-state plasma concentrations, are typically reached within one to two weeks of starting multiple daily doses. The onset of full symptom changes is typically gradual and varies among patients.


Q: Are there any long-term side effects associated with Klomipramin use?

Regulatory documents list many possible adverse reactions that occur during treatment. However, the official summary of clinical trials notes that the long-term effects are not fully established, and there is limited information regarding the sustained stability or safety profile for long-term maintenance use.


Q: Can you take Klomipramin with pain relievers like ibuprofen?

The official documentation advises caution when using Klomipramin with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This combination may increase the risk of bleeding. Disclosure of all co-administered medicines to a healthcare provider is noted as important for risk assessment.


Q: Are there known interactions between Klomipramin and cold or flu medicines?

Official prescribing information cautions against co-administration with other drugs that affect serotonin levels or those that prolong the QTc interval (an electrical measurement of the heart). Regulatory documents state that certain ingredients commonly found in cold and flu medicines may fall into these risk categories.


Q: Can Klomipramin be taken with food?

Yes. According to official administration instructions, initial doses are often taken with meals. This is typically recommended to help reduce the chance of experiencing gastrointestinal discomfort. Regulatory data indicates that food generally does not affect how the body absorbs the medicine.


Q: Does Klomipramin cause sexual side effects?

Yes, official prescribing information documents that Klomipramin can be associated with sexual side effects. These can include issues like decreased libido, abnormal ejaculation, and difficulty achieving orgasm (anorgasmia) in both men and women.


Q: Does Klomipramin cause weight gain?

Official studies indicate that weight gain is a reported adverse reaction. Clinical studies reviewed by regulators reported that a percentage of patients experienced a weight gain of at least 7% of their initial body weight.


Q: Is Klomipramin safe to use during pregnancy?

Klomipramin is not generally recommended for use during pregnancy. Regulatory text states that the medicine is reserved only for situations where the potential benefit to the mother is considered to outweigh the potential risk to the fetus.


Q: Is it difficult to stop taking Klomipramin?

Regulatory documents mandate that the dose must be gradually tapered prior to stopping the medicine completely. Official procedure notes that abrupt cessation may lead to discontinuation symptoms such as nausea, dizziness, and headache.


Q: Does Klomipramin affect coordination or driving ability?

Yes. Official documents warn that Klomipramin may cause drowsiness, dizziness, or blurred vision. These central nervous system effects may impair a person's physical reactions and their ability to safely drive or operate machinery.


Q: Are there any common supplements that interact with Klomipramin?

Official documents specifically caution against the concurrent use of the herbal supplement St. John's Wort. This is due to the potential for it to combine with Klomipramin to increase the risk of Serotonin Syndrome, a serious condition related to elevated serotonin activity.


Q: What are the risks if I accidentally take too much Klomipramin?

Accidental overdose is a serious medical emergency. Critical manifestations documented in regulatory texts include severe effects on the heart (cardiac dysrhythmias), severe hypotension (very low blood pressure), and CNS depression, which can lead to coma. Immediate medical care is required.


Q: Is Klomipramin used to treat anxiety?

Klomipramin is officially indicated for the treatment of Obsessive-Compulsive Disorder (OCD). The research evidence also supports its use for conditions like Panic Disorder, which is characterized by fluctuating anxiety symptoms.


Q: Can Klomipramin make me sensitive to the sun?

Official product information notes that Klomipramin can cause photosensitivity. This means the skin may become more sensitive to sunlight than usual, increasing the risk of getting sunburn or other skin reactions.


Q: Is there a maximum recommended period for using Klomipramin?

Regulatory summaries indicate that the clinical research base primarily involves short-term clinical trials. Because of this, information is limited regarding the sustained stability or long-term outcomes for maintenance treatment.


Q: Does Klomipramin show up on drug tests?

Klomipramin and its major active metabolite, norclomipramine (desmethylclomipramine), can be measured in the blood. These substances may be detected during therapeutic drug monitoring or as part of a toxicology screening to evaluate potential toxicity.


Q: Are there any specific risks of Klomipramin for men vs. women?

Regulatory documents report adverse events based on gender, particularly concerning sexual dysfunction. Specific side effects like abnormal ejaculation and impotence are documented in men, while overall sexual function changes are noted for both men and women.

How should Klomipramin be stored and disposed of?

Storage and Disposal of Klomipramin (Clomipramine Hydrochloride)

Clomipramine hydrochloride must be stored according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

Requirement Condition
Temperature Controlled Room Temperature (20 to 25C)
Container Tight, light-resistant container
Protection Protect from moisture

Storage must ensure the medicine remains out of the sight and reach of children, and the container should have a child-resistant closure. Exposure to temperatures outside the permissible range should be avoided.

Disposal Instructions

Klomipramin is not on the FDA's list of medicines recommended for immediate disposal by flushing. Unused or expired medication should be disposed of by utilizing an authorized drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klomipramin found in:

A-Z Index: